

# Hepatitis B virus infection has no significant role on lymphoproliferative disorders post liver transplantation: PTLD. int survey

Morteza Izadi,\* Saeed Taheri\*\*,\*\*

\* Health Research Center; Baqiyatallah University of Medical Sciences, Tehran, Iran.

\*\* Dr Taheri Medical Research Group, Tehran, Iran. \*\*\* International Travel Medicine Center of Iran; Tehran, Iran.

## ABSTRACT

**Introduction.** Based on very limited data, it has been recently suggested that hepatitis B virus infection can play significant roles in post transplantation lymphoproliferative disorders. In the current study pooling data of PTLD in HBV positive liver recipients gathered from the existing literature, we sought to analyze and compare characteristics, behavior and prognosis of PTLD arising in HBV positive liver graft recipients. **Methods.** A comprehensive search for the available data through PubMed and Google Scholar for reports of PTLD and HBV infection in liver recipients was conducted. Data of 18 different studies were pooled and analyzed. **Results.** Liver recipients with HBV positive-PTLD were comparable to their HBV negative counterparts in gender, age at transplantation, time from transplantation to PTLD development, lymphoma cell type, histopathology of lesions, remission episodes, mortality rate, multi-organ involvement, and disseminated PTLD ( $p > 0.1$  for all). HBV positive PTLD patients were significantly less likely to complicate spleen (0 vs. 23%, respectively;  $p = 0.015$ ). Survival of the two patient groups were comparable ( $p = 0.8$ ). **Conclusion.** HBV infection has no significant impact on inducing some distinct types of PTLD and represents no survival effect in PTLD setting. Future prospective studies are needed for confirming our findings.

**Key words.** Hepatitis B. Lymphoproliferative disorders. Liver transplantation.

## INTRODUCTION

During the past two decades, due to enhancements in preventive and therapeutic methods, the organ transplantation practice has witnessed substantial improvements in the outcome of organ recipients, especially within their early post transplantation period.<sup>1</sup> These advantages have resulted in an increase in the survival of transplant patients; and expression of some newly emerged complications adversely affecting the outcome of the practice.

Lymphoproliferative disorders after solid organ transplantation (PTLD) is one of the most prevalent malignancies that develops in organ recipients, and remains a challenging diagnostic and therapeutic

problem in the context of transplantation. PTLD is characterized by lymphoid proliferation of B- or T-cell origin and was first reported by Penn, et al.,<sup>2</sup> in 1969, in a patient who had undergone living related kidney transplantation. Since then, several reports have been published indicating a high incidence of PTLD among recipients of all types of organs, including liver. The incidence of lymphomas after transplantation is quite higher than that in the general population.<sup>3-8</sup> Reported reasons for this high incidence include greater levels of immunosuppression, antibody induction therapy including OKT3, anti-lymphoblast globulin (ALG) and antithymocyte globulin (ATG) and viral infections especially Epstein-Barr virus (EBV) infection.<sup>6-8</sup>

Evidence suggests that hepatitis B virus (HBV) can act as a lymphotropic virus in the normal population and has been implicated as a risk factor for the development lymphoproliferative disorders.<sup>9,10</sup> The prevalence of HBV among non-Hodgkin's lymphoma (NHL) patients has been reported high in hepatitis B endemic areas.<sup>11</sup> Moreover, it is

Correspondence and reprint request: Dr. Morteza Izadi  
Floor 3; Headquarters' Building, Baqiyatallah Hospital  
Mollasadra st, Vanak sq. Tehran, Iran

Manuscript received: March 04, 2011  
Manuscript accepted: March 21, 2011

demonstrated that chronic HBV infection is associated with a higher incidence of NHL in non-transplant population<sup>9</sup> and patients with B cell NHL reportedly represent higher prevalence of HBV infection.<sup>10</sup> The first evidence indicating a potential association between HBV infection and PTLD development has been published in 2008 as a series of three;<sup>12</sup> and one year later in 2009, Zhang, *et al.*<sup>13</sup> published another report confirming a possible association between HBV infection and PTLD. Taken together, existing data suggests that HBV can play a pathogenic role in inducing NHL both in the general population and organ transplant patients.

Although there are some evidences indicating the impact of HBV on the development of PTLD, however as mentioned above, the existing data are based on very limited number of case reports or small series; moreover, there is no mention whether PTLD arising in HBV positive patients represents any special features and prognosis. Due to the limited number of reports, there is almost no data on any potential specificity for HBV induced PTLD. In fact, such cases are only included in bigger series and have not received enough attention. Pooling data of PTLD in HBV positive liver recipients from the existing literature, we sought to analyze and compare characteristics, behavior and prognosis of PTLD arising in HBV positive liver graft recipients.

## MATERIALS AND METHODS

### Approach to the study

We conducted a comprehensive search for the available data through PubMed and Google Scholar for reports of PTLD and HBV infection. Search terms used were:

- Lymphoproliferative disorders + transplantation + liver + hepatitis B virus.
- Lymphoproliferative disorders + transplantation + liver + HBV.
- PTLD + liver + hepatitis B virus.
- PTLD + liver + HBV.

In cases where we were not able to obtain the full text of the article, emails were sent to correspondent authors requesting the article. Of the full texts obtained, we only included studies in which data on each patient was presented separately. To minimize selection bias, HBV negative PTLD controls were included only from the same studies, cases were enrolled from. A standard questionnaire was developed

to collect data from different published studies. The time between transplantation and PTLD onset was defined as the period between the engraftment and the first signs of PTLD or diagnosis, depending on the study's approach.

### Study population

Eighteen international published studies<sup>12-29</sup> were found that met our criteria. A total of 151 cases of PTLD liver transplant patients were included in the analysis; of whom 42 (28%) were HBV positive-PTLD and the remaining 109 (72%) patients had developed HBV negative-PTLD. EBV status was documented in 107 (71%) patients, of whom 73 (68%) were reported positive.

Because methodologies differed among the published studies, not all our measures were available for all patients. We recorded disseminated PTLD when it was reported by the study authors or if at least three different organs were involved by the PTLD (different lymph node areas were excluded from analysis due to lack of knowledge on how to categorize; unless they were concomitant with other organs involvements; or other authors specifically presented them as having disseminated disease). According to the abovementioned, disseminated disease was reported for 20 patients (23%; 64 missing data). Multi-organ involvement, defined as involvement of more than one organ (the second organ could be a lymphatic region), was available in 36 patients (40%; 61 missing data).

At PTLD onset, all patients were under immunosuppressive regimens consisting of varying combinations of azathioprine, prednisone, cyclosporine, mycophenolate mofetil, ATG/ALG and OKT3. A rather uniform approach was used to manage most of the included PTLD liver recipients. On diagnosis of PTLD, the first step in almost all reports was to decrease or discontinue immunosuppressive therapy; various regimens of chemotherapy with or without surgical interventions were also used for some patients.

### Response to treatment

We defined response to treatment as any favorable change both in PTLD measures as well as the patient's clinical condition. Data on response to treatment was reported for 38 patients (25%), of whom 28 (74%) responded to treatment. To create a common standard across the studies, we defined a remission episode as when a patient was alive 24

months after PTLT onset (because all reported cases meeting this criterion had at least one confirmed remission episode) and no remission as when a patient died within the first month after PTLT onset (because there were no patients dying at the first post-transplant month that was reported to have any remission episodes). According to these criteria, data on remission was available for 70 patients (47%), of whom 58 (83%) had at least one response to treatment, irrespective of their future disease course. Data on mortality was available for 100 patients (67%), of whom 39 (39%) died. We defined death due to PTLT when the authors stated it, death was within 6 months after onset, or death was reported to be due to PTLT treatment complications. Based on these criteria, 17 patients (44% of reported deaths, 29% of patients for whom mortality data was reported) died due to PTLT.

### Statistical analysis

SPSS v.13.0 software was used for data analyses. Statistical comparisons between patient subgroups were performed using chi-square and Fisher's exact tests for proportions, and the Student's t-test for continuous data. Survival analysis was done with life tables, Kaplan-Meier method and log-rank test. A p-value of 0.05 was taken as the threshold for significance.

## RESULTS

Overall, 151 cases of PTLT were found. There were 96 (64%) male and 51 (36%) female patients (4 missing data). Mean age at onset was  $45.4 \pm 15.0$  years. The mean interval between transplantation and the onset of PTLT was  $38.0 \pm 37.5$  months and the mean follow up time after onset of PTLT was  $23.5 \pm 31.2$  months.

Characteristics of PTLT patients with and without HBV infection are summarized in table 1. Chi-square test showed that HBV positive-PTLT patients were comparable to HBV negative-PTLT in gender ( $p = 0.18$ ), age at transplantation ( $p = 0.976$ ), time from transplantation to PTLT development ( $p = 0.326$ ), lymphoma cell type ( $p = 0.16$ ), remission ( $p = 0.75$ ), mortality rate ( $p = 0.66$ ), multi-organ involvement (based on our definition;  $p = 0.46$ ); and disseminated PTLT (based on our definition;  $p = 0.57$ ). Histopathological evaluations were also not significantly different between the two groups ( $p = 0.11$ ).

Table 2 compares HBV-positive vs. HBV-negative PTLT respecting organ involvements by the PTLT. HBV positive PTLT patients were significantly less likely to complicate spleen (0 vs. 23%, respectively;  $p = 0.015$ ); but no other differences were seen for the two patient groups. At the last follow up, 39 patients (39% of reported; 50 missing data) were dead.


**Table 1.** Characteristics of liver transplant recipients.

Variables	Study groups		p value	Available data
	HBV+	HBV-		
• Age (yr)	45.4 ± 10.5	45.3 ± 16.4	0.976	140
• Gender male (%)	29 (74)	67 (62)	0.177	147
• Time to PTLT development (mo)	43.7 ± 40.3	36.0 ± 36.5	0.326	120
• Time from diagnosis to death (mo; dead patients included only)	11.1 ± 18.5	10.0 ± 18.7	0.879	34/39
• Multi organ involvement (%)*	11 (47.8)	25 (37.9)	0.464	89
• Disseminated PTLT (%)*	6 (27.3)	14 (21.9)	0.575	86
• Immunosuppression (azathioprine based) (%)**	10 (33.3)	25 (42.4)	0.335	89
• Lymphoma cell type B cell (%)	27 (90)	67 (97.1)	0.162	99
• Morphology			0.112	91
◦ Early lesion (Plasmacytic hyperplasia)	0	2 (3.2)	-	-
◦ Polymorphic B cell lymphoma	6 (20.7)	24 (38.7)	-	-
◦ Monomorphic PTLT	22 (75.9)	36 (58.1)	-	-
◦ Hodgkin lymphoma	1 (3.4)	0	-	-
• EBV status (%)	14 (60.9)	59 (70.2)	0.451	107
• Mortality rate (%)	11 (34.4)	28 (41.2)	0.661	100
• Remission episode (%)***	19 (86.4)	26 (86.7)	1.0	52
• Remission episode (%)*	24 (85.7)	34 (81)	0.751	70
• Use of induction therapy (%)	7 (36.8)	26 (49.1)	0.428	72

\* According to the criteria defined in the methods section. \*\* Vs. under MMF and/or FK-506 based immunosuppression. \*\*\* Author reported.

**Table 2.** Frequency of involved organs in 168 liver transplant recipients with early or late onset PTLD.

Involved organs	HBV infection		p value	Available data
	HBV+	HBV-		
Orbital	0	1(1.8)	1.0	79
Skin	1(4.5)	0	0.278	79
Genitalia	2(9.1)	0	0.075	79
CNS	1(4.5)	3(5.3)	1.0	79
Spleen	0	13(22.8)	0.015	79
Colon	2(9.5)	3(5.5)	0.612	76
Small intestine	3(14.3)	4(7.1)	0.383	77
Renal involvement	1(4.5)	1(1.8)	0.482	79
Liver involvement	11(45.8)	45(54.4)	0.349	101
Respiratory system	4(20)	11(22.4)	1.0	69
Bone marrow	4(18.2)	10(17.5)	1.0	79

**Figure 1.** Survival curves of HBV-positive and -negative PTLD patients (death of any cause as the outcome).

Using death by any cause as the final outcome, log-rank test did not show any difference between the two groups in survival ( $p = 0.78$ ) (Figure 1). Nor was any difference seen between the two groups when only death due to PTLD (based on our definition) was used as the final outcome ( $p = 0.36$ ). Five-year survival rate for HBV-positive PTLD patients was 64% compared to 56% for HBV-negative PTLD patients.

## DISCUSSION

PTLD is a potentially fatal complication of transplantation in all types of organ recipients. The incidence, features and prognosis of PTLD varies

between different organ transplant patients due to several interfering factors including the transplanted organ, doses of immunosuppression used, the use of antibody induction, and viral infections most notably EBV infection.<sup>31-33</sup> In non-transplant setting, hepatophil viruses are shown to have provocative roles in inducing lymphoproliferative disorders. Recently, it has been suggested that HBV reactivation after transplantation is a risk factor for the development of PTLD.<sup>12,13</sup> One reason for this risk enhancement is reportedly the immunosuppressive treatment in these patients due to preventing rejection episodes leading to reactivation of chronic infections including HBV.

In this study of international data, we gathered the existing data from HBV infected liver transplant recipients who had developed PTLD in their disease course to analyze and search any potential associations between HBV infection in PTLD patients and PTLD features, behavior and prognosis in liver graft recipients. The unexpected finding of this study is that we found almost no difference between HBV positive and negative PTLD patients. Although, there might be some criticisms on the methodology of our study which would be later discussed, we think that this finding is not only due to the limited number of included patients because to the best of our knowledge, there is no other study that has investigated even a comparable number of HBV positive patients in PTLD setting.

Moreover, this topic has not been previously discussed except for a series of 3 cases<sup>12</sup> and one case report<sup>13</sup> and they have provided the first evidence for a potential association between HBV infection and PTLD. On the other hand, methodology of our study which reviews and gathers data from different reports, despite some disadvantages, can be used precisely

in several cases. For example, if HBV infection could have a provocative role for development of PTLD, at least we should expect a shorter time from transplantation to PTLD development in HBV positive PTLD patients compared to HBV negative controls; as we can observe it in EBV positive patients in transplantation setting.<sup>32,33</sup> Moreover, no disparities were also found in the behavior of the PTLD between HBV-positive and -negative liver recipients including remission rates and survival rates. This finding suggests that, even if HBV has any role in the development of the PTLD, it does not induce a more malevolent or fatal form of the disease than that in non-infected subjects. An interesting observation was that HBV positivity was not associated with a hepatic localization of the PTLD; the only disparity found between the two groups was a less likelihood of HBV positive PTLD lesions to complicate the spleen. In fact, none of HBV positive subjects represented a spleen complication while 23% of HBV negative controls developed splenic involvement by PTLD. Although we have no explanation for this observation, the considerable difference observed cannot be simply disregarded as an incidence.

To exclude any simultaneous messing effects of hepatitis C virus infection on our results (5 cases), we reanalyzed our data after excluding these cases. No change has been observed after the adjustment (data not shown). Rituximab has also been reported to reactivate HBV infection and as a consequence it might play as a stimulating factor for the development of lymphoma.<sup>34-36</sup> Unfortunately, we only had data of our patients after the development of the PTLD; so, we were not able to investigate a potential impact of rituximab on HBV-associated PTLD.

Nevertheless, we analyzed data of our HBV positive PTLD liver recipients with respect to having (10; 24%) or not having (32; 76%) a history of rituximab treatment after PTLD emergence. We found that patients under rituximab treatment significantly had higher rate of multi-organ disease (data not shown); but it probably was the rationale for which rituximab was employed for these patients. Moreover, we found no survival difference between HBV positive patients who had or had not used rituximab; this can confirm current study's findings that HBV has no prominent role in the prognosis of the PTLD; since despite its HBV activating role, rituximab had no deteriorating impact on the outcome of HBV positive PTLD patients. Due to the very limited number of cases with a history of antiviral therapy, we were not able to evaluate potential impact of antiviral agents on the PTLD outcome.

Potential criticisms may arise over our study. First, our study population was gathered from different reports with inconsistent approaches. We also believe that this is the unique major limitation for this study leading to substantial missing data for some of study variables and thus, decreasing the power of our analyses. This limitation was most prominent for special data that are not typically included in reports on PTLD patients. Another limitation due to the inconsistencies available between the included studies was that results of different studies were not presented in the same way. For example, report of any response to treatment was presented very dissimilarly in different studies; while in one study partial and complete remission was used to translate the results, in another only "response to treatment" was used and in some others no specific terminology was employed. So, we ought to invent new methods to cumulate the existing data for analysis.

We conclude that, HBV infection has no significant impact on inducing some distinct types of PTLD and represents no survival effect in PTLD setting. Future prospective studies are needed for confirming our findings.

## REFERENCES

1. Pourfarziani V, Ramezani MB, Taheri S, Izadi M, Einollahi B. Immunogenicity of pneumococcal vaccination in renal transplant recipients and hemodialysis patients: a comparative controlled trial. *Ann Transplant* 2008; 13(3): 43-7.
2. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patents. *Transplant Proc* 1969; 1(1): 106-12.
3. Levy M, Backman L, Husberg B, et al. De novo malignancy following liver transplantation: a single-center study. *Transplant Proc* 1993; 25(1, Pt. 2): 1397-9.
4. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. *Am J Pathol* 1988; 133(1): 173-92.
5. Stieber AO, Boillot O, Scotti-Foglieni C, et al. The surgical implications of the posttransplant lymphoproliferative disorders. *Transplant Proc* 1991; 23(1, Pt. 2): 1477-9.
6. Malatack JF, Gartner JC Jr, Urbach AH, Zitelli BJ. Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern. *J Pediatr* 1991; 118(5): 667-75.
7. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. *Transplant Proc* 1991; 23(1, Pt 2.): 1473-6.
8. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. *Transplantation* 1995; 59(4): 524-9.
9. Ulcickas YM, Quesenberry CP Jr, Guo D, et al. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. *Hepatology* 2007; 46: 107.



10. Wang F, Xu RH, Han B, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. *Cancer* 2007; 109: 1360.
11. Kim JH, Bang YJ, Park BJ, et al. Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. *Jpn J Cancer Res* 2002; 93: 471.
12. Luo Y, Zhang AB, Huang H, Zheng SS. Is hepatitis B virus reactivation a risk factor in the development of post-transplant lymphoproliferative disorder following liver transplantation? *Chin Med J* 2008; 121(13): 1237-40.
13. Zhang A, Zhang M, Shen Y, Wang W, Zheng S. Hepatitis B virus reactivation is a risk factor for development of post-transplant lymphoproliferative disease after liver transplantation. *Clin Transplant* 2009; 23(5): 756-60. Epub 2009 Aug 2.
14. McCormack L, Hany TI, Hübner M, Petrowsky H, Mullhaupt B, Knuth A, et al. How useful is PET/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation? *Am J Transplant* 2006; 6(7): 1731-6.
15. Aseni P, Vertemati M, De Carlis L, Sansalone CV, Bonacina E, Minola E, et al. De novo cancers and post-transplant lymphoproliferative disorder in adult liver transplantation. *Pathol Int* 2006; 56(11): 712-5.
16. Nagarsheth NP, Kalir T, Rahaman J. Post-transplant lymphoproliferative disorder of the cervix. *Gynecol Oncol* 2005; 97(1): 271-5.
17. Dhillion MS, Rai JK, Gunson BK, Olliff S, Olliff J. Post-transplant lymphoproliferative disease in liver transplantation. *Br J Radiol* 2007; 80(953): 337-46. Epub 2007 Mar 28.
18. Burra P, Buda A, Livi U, Rigotti P, Zanusi G, Calabrese F, et al. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection? *Eur J Gastroenterol Hepatol* 2006; 18(10): 1065-70.
19. Cano B, Sanchez G, Montoliu G, Insa S, Masb F, Calderero V, et al. Imaging of liver-localized post-transplantation lymphoproliferative disease as complication of liver transplantation. *Eur J Radiol Ext* 2004; 49: 61-6.
20. Baccarani U, Piselli P, Serraino D, Adani GL, Lorenzin D, Gambato M, et al. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. *Dig Liver Dis* 2010; 42(1): 55-60. Epub 2009 Jun 3.
21. Lemoine A, Pham P, Azoulay D, Saliba F, Emile JF, Saffroy R, et al. Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants. *Blood* 2001; 98(5): 1332-8.
22. Lorenzini S, Andreone P, Gramenzi A, et al. Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases. *Transplant Proc* 2006; 38: 1477-80.
23. Nuckols JD, Baron PW, Stenzel TT, Olatidoye BA, Tuttle-Newhall JE, Clavien PA, Howell DN. The pathology of liver-localized post-transplant lymphoproliferative disease: a report of three cases and a review of the literature. *Am J Surg Pathol* 2000; 24(5): 733-41. Review.
24. De Diego JI, Prim MP, Hardisson D, Verdaguier JM, Jara P. Post-transplant lymphoproliferative disease in tonsils of children with liver transplantation. *Int J Pediatr Otorhinolaryngol* 2001; 58(2): 113-8.
25. Zimmermann T, Hoppe-Lotichius M, Tripkovic V, Barreiros AP, Wehler TC, Zimmermann A, et al. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). *Eur J Intern Med* 2010; 21(3): 208-15.
26. Norin S, Kimby E, Ericzon BG, Christensson B, Sander B, Söderdahl G, Hägglund H. Posttransplant lymphoma—a single-center experience of 500 liver transplantations. *Med Oncol* 2004; 21(3): 273-84.
27. Capello D, Cerri M, Muti G, Berra E, Oreste P, Deambrogi C, et al. Molecular histogenesis of posttransplantation lymphoproliferative disorders. *Blood* 2003; 102: 3775-85.
28. Avolio AW, Agnes S, Barbarino R, Magalini SC, Frongillo F, Pagano L, et al. Posttransplant lymphoproliferative disorders after liver transplantation: analysis of early and late cases in a 255 patient series. *Transplant Proc* 2007; 39(6): 1956-60.
29. Rohr JC, Wagner HJ, Lauten M, Wacker HH, Jüttner E, Hanke C, et al. Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. *Pediatr Transplant* 2008; 12(4): 426-31.
30. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. *Lancet* 1993; 342: 1514-6.
31. Izadi M, Taheri S. Features, predictors and prognosis of lymphoproliferative disorders post-liver transplantation regarding disease presentation time: Report from the PTLD.Int survey. *Ann Transplant* 2011; 16(1): 39-47.
32. Khedmat H, Alavian SM, Taheri S. Significance of Epstein-Barr virus infection in the outcome of renal transplant patients with lymphoproliferative disorders. *Ann Transplant* 2010; 15(2): 40-4.
33. Izadi M, Taheri S. Significance of in situ hybridization results for EBV-encoded RNA in post-transplantation lymphoproliferative disorder setting: Report from the PTLD.Int survey. *Ann Transplant* 2010; 15(4): 102-9.
34. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab [Letter]. *N Engl J Med* 2001; 344: 68-9.
35. Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. *Ann Hematol* 2001; 80: 549-52.
36. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. *J Clin Oncol* 1999; 17: 268-76.